Tom3 schreef op 13 januari 2021 19:04:
Gelezen op SA ( geschreven door een m.i. gerespecteerde investeerder/belegger):
Well, apparently the ICE approach does lead to an attack on cancerous cells as AFM13 has shown. The side-effect profile for HL is superior than SGEN's ADC brentuximab vedotin. EGFR-targeting ICE AFM24 is currently in the dose escalation studies, the initial low dose did not cause any adverse events, but this dose was below efficacy. They should be releasing more data soon. I think the raise of 100M was just in case, leaving the other half of the filed shelf for a raise if the results are explosively good for the share price. They now have so many different trials running so funding is inevitable.